Phase 2 preliminary discovers Chinese COVID-19 antibody is sheltered, incites insusceptible reaction: Lancet study Kumar Jeetendra | July 21, 2020 A phase II clinical trial of a COVID-19 vaccine candidate, conducted in China, has found it is safe and causes an immune reaction, a study published in The Lancet says. Researchers, for example those from the Center for Disease Control and Prevention, said the trial sought to assess the safety and immunogenicity of this vaccine …
Cipla Health signs agreement to acquire Endura Mass Kumar Jeetendra | July 14, 2022 Mumbai, India; July 14, 2022: Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as “Company” or “Cipla”) announced today that Cipla Health Limited (CHL), wholly owned subsidiary and consumer healthcare arm of the Company has signed definitive agreements for acquisition of Endura Mass, a renowned nutritional supplement brand in the category of …
